Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China
Our study found that NSCLC patients with HER2 exon 20 oncogenic variants have a higher risk of metastasis and drug resistance, leading to worse outcomes than non-exon 20 mutations. This highlights the urgent need for targeted therapies aimed at exon 20 insertions to improve survival and treatment outcomes in this subgroup.
Authors
- Zichuan Liu (ORCID: https://orcid.org/0000-0002-5709-8497)
- Zhuoyun Zhang
- Yisheng Huang (ORCID: https://orcid.org/0000-0002-3654-6561)
- Yating Hou (ORCID: https://orcid.org/0000-0001-5684-2475)
- Wei Luo (ORCID: https://orcid.org/0000-0002-8319-3527)
- Mingyu Zhou (ORCID: https://orcid.org/0000-0002-2370-8939)
- D Mai
- Xingyang Xue
Institutions
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1186/s12885-025-14125-9
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Natural Science Foundation of Guangdong Province